| Dr Donald Wayne Hohman Jr, MD | |
|
7777 Forest Ln Ste C106, Dallas, TX 75230-6831 | |
| (972) 566-5564 | |
| Not Available |
| Full Name | Dr Donald Wayne Hohman Jr |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 16 Years |
| Location | 7777 Forest Ln Ste C106, Dallas, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801235833 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0114X | Orthopaedic Surgery - Adult Reconstructive Orthopaedic Surgery | P9200 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Home Care Network | Palestine, TX | Home health agency |
| Medical City Dallas Hospital | Dallas, TX | Hospital |
| Texas Institute For Surgery At Presbyterian Hospit | Dallas, TX | Hospital |
| Medical City Plano | Plano, TX | Hospital |
| Texas Health Center For Diagnostics & Surgery | Plano, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Joint Institute, Pllc | 8325206584 | 31 |
News Archive
Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.
ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.
On March 31, 2011, H&Q Healthcare Investors paid a stock distribution of $0.31 per share. It is estimated that this distribution is derived from long-term capital gains.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.
As part of ongoing efforts to improve patient services, the Department of Radiology at UC San Diego is participating in the Enterprise Patient Flow (EPF) Study. UC San Diego Medical Center will implement the On-Cue™ System - developed by Allocade, Inc., a developer of innovative healthcare software solutions - to study process improvement, resource utilization, communication and patient experience.
› Verified 9 days ago
| Entity Name | Texas Orthopaedic Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134360241 PECOS PAC ID: 8527042217 Enrollment ID: O20040618000193 |
News Archive
Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.
ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.
On March 31, 2011, H&Q Healthcare Investors paid a stock distribution of $0.31 per share. It is estimated that this distribution is derived from long-term capital gains.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.
As part of ongoing efforts to improve patient services, the Department of Radiology at UC San Diego is participating in the Enterprise Patient Flow (EPF) Study. UC San Diego Medical Center will implement the On-Cue™ System - developed by Allocade, Inc., a developer of innovative healthcare software solutions - to study process improvement, resource utilization, communication and patient experience.
› Verified 9 days ago
| Entity Name | Texas Joint Institute, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700160744 PECOS PAC ID: 8325206584 Enrollment ID: O20120220001104 |
News Archive
Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.
ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.
On March 31, 2011, H&Q Healthcare Investors paid a stock distribution of $0.31 per share. It is estimated that this distribution is derived from long-term capital gains.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.
As part of ongoing efforts to improve patient services, the Department of Radiology at UC San Diego is participating in the Enterprise Patient Flow (EPF) Study. UC San Diego Medical Center will implement the On-Cue™ System - developed by Allocade, Inc., a developer of innovative healthcare software solutions - to study process improvement, resource utilization, communication and patient experience.
› Verified 9 days ago
| Entity Name | Total Joint Cin Of North Texas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023523669 PECOS PAC ID: 6103188578 Enrollment ID: O20180322002039 |
News Archive
Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.
ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.
On March 31, 2011, H&Q Healthcare Investors paid a stock distribution of $0.31 per share. It is estimated that this distribution is derived from long-term capital gains.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.
As part of ongoing efforts to improve patient services, the Department of Radiology at UC San Diego is participating in the Enterprise Patient Flow (EPF) Study. UC San Diego Medical Center will implement the On-Cue™ System - developed by Allocade, Inc., a developer of innovative healthcare software solutions - to study process improvement, resource utilization, communication and patient experience.
› Verified 9 days ago
| Entity Name | Otx Care Of Tx, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386106078 PECOS PAC ID: 3072946664 Enrollment ID: O20191212002488 |
News Archive
Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.
ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.
On March 31, 2011, H&Q Healthcare Investors paid a stock distribution of $0.31 per share. It is estimated that this distribution is derived from long-term capital gains.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.
As part of ongoing efforts to improve patient services, the Department of Radiology at UC San Diego is participating in the Enterprise Patient Flow (EPF) Study. UC San Diego Medical Center will implement the On-Cue™ System - developed by Allocade, Inc., a developer of innovative healthcare software solutions - to study process improvement, resource utilization, communication and patient experience.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donald Wayne Hohman Jr, MD 7777 Forest Ln Ste C106, Dallas, TX 75230-6831 Ph: (972) 566-5564 | Dr Donald Wayne Hohman Jr, MD 7777 Forest Ln Ste C106, Dallas, TX 75230-6831 Ph: (972) 566-5564 |
News Archive
Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.
ProFibrix B.V., a leader in the development of innovative bioactive products to stop bleeding (hemostasis), today announced the start of its pivotal Phase III clinical trial with Fibrocaps (FINISH-3) in spine, liver, vascular and soft tissue surgery.
On March 31, 2011, H&Q Healthcare Investors paid a stock distribution of $0.31 per share. It is estimated that this distribution is derived from long-term capital gains.
The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability.
As part of ongoing efforts to improve patient services, the Department of Radiology at UC San Diego is participating in the Enterprise Patient Flow (EPF) Study. UC San Diego Medical Center will implement the On-Cue™ System - developed by Allocade, Inc., a developer of innovative healthcare software solutions - to study process improvement, resource utilization, communication and patient experience.
› Verified 9 days ago
Dr. Christopher Michael Sakowski, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7115 Greenville Ave Ste 310, Dallas, TX 75231 Phone: 214-265-3200 Fax: 214-265-3285 | |
Sumant G Krishnan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 9301 N Central Expy, Suite 400, Dallas, TX 75231 Phone: 214-220-2468 Fax: 214-397-1555 | |
Jorge Casas, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 12222 N Central Expy, Suite 210, Dallas, TX 75243 Phone: 214-615-1949 Fax: 214-615-1949 | |
Nathan Bruck, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 411 N Washington Ave Ste 7000, Dallas, TX 75246 Phone: 214-823-7090 Fax: 214-823-1644 | |
Dr. Michael Wheeler, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln Ste 130, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-750-8504 | |
Dr. Richard S Levy, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 6901 Snider Plz, Ste 200, Dallas, TX 75205 Phone: 214-369-7733 Fax: 214-360-9604 | |
Dr. Robert Russell Scheinberg, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8210 Walnut Hill Ln, Ste 130, Lb 11, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 |